The ADEPT-2 study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Cobenfy in subjects with psychosis associated with Alzheimer’s disease ...
Researchers pored through a year’s worth of Benzinga Analyst Ratings data, looking for signals. Data specialists at investment dashboard provider Toggle.ai uncovered that the analyst insights Benzinga ...
Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback